Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

@article{Davis1995PreclinicalPE,
  title={Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.},
  author={Charles B. Davis and Timothy W Hepburn and James J Urbanski and Deborah Kwok and Timothy K. Hart and Danuta J. Herzyk and Sandra G Demuth and Michelle Leland and Gerry R. Rhodes},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={1995},
  volume={23 10},
  pages={1028-36}
}
A preclinical evaluation of RSHZ19, a respiratory syncytial virus-specific reshaped human monoclonal antibody (IgG1 framework), has included pharmacokinetic studies in rats, adult cynomolgus macaques, and infant baboons after intravenous (iv), subcutaneous, or intramuscular (im) administration. After iv administration to rats and monkeys (1 mg/kg dose), a biphasic decline in plasma concentration was observed. The dominant terminal phase was characterized by an 11-day half-life in rats and a 21… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…